Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNE1 | P24864 | 20/20 | 0.47 |
| ▸ | CDK2 | P24941 | 20/20 | 0.47 |
| ▸ | CCND1 | P24385 | 16/20 | 0.47 |
| ▸ | CDK6 | Q00534 | 16/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.47 |
| ▸ | CDK9 | P50750 | 5/20 | 0.47 |
| ▸ | CDK4 | P11802 | 4/20 | 0.47 |
| ▸ | CCND3 | P30281 | 1/20 | 0.44 |
| ▸ | RB1 | P06400 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15041479 | 0.94 | CCNE1 (0.46) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL13553927 | 0.91 | CCND1 (0.40) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL15036158 | 0.76 | CCNE1 (0.44) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL14682026 | 0.74 | CDK2 (0.41) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL15787912 | 0.73 | CCND1 (0.47) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL14682065 | 0.72 | CDK2 (0.44) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL15041463 | 0.71 | CDK2 (0.43) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL15785377 | 0.71 | CDK4 (0.50) | CCNE1CDK2CCND1CDK6CCNT1 | |
| SCHEMBL15788013 | 0.71 | TNK2 (0.42) | — | |
| SCHEMBL3673672 | 0.71 | CCNE1 (0.68) | CCNE1CDK2CCND1CDK6CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-8372970-B2 | 8-ethyl-6-(aryl)pyrido[2,3-D]pyrimidin-7(8H)-ones for the treatment of CNS disorders | AFRAXIS, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035335-A1 | 8-ETHYL-6-(ARYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK6, PAK5 | CCNE1 3907/4885CDK2 259/4885CCND1 4243/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | CCNE1 1585/4885CDK2 183/4885CCND1 2153/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.